Роль радиочастотной термодеструкции в современной стратегии лечения больных злокачественными опухолями печени. Обзор литературы

Радиочастотная термодеструкция (термоабляция) остается одним из наиболее востребованных методов локального разрушения опухолей печени. Накоплен многолетний мировой опыт применения в онкологии, опубликовано множество исследований, и практические вопросы редко становятся предметом дискуссий. Вместе с тем все еще остаются стратегические вопросы: когда, кому, в каких ситуациях? По сути, признавая эффективность воздействия, специалисты не всегда уверены, при каких обстоятельствах потенциал радиочастотной термодеструкции будет реализован максимально. В обзоре литературы обобщен мировой опыт применения термоабляции при злокачественных опухолях печени. Сделана попытка выделить ключевые позиции при определении стратегии лечения с применением технологии. Безусловный приоритет в выработке оптимального лечения больных злокачественными опухолями печени имеет междисциплинарная кооперация.

печень, злокачественное новообразование, метастазы, радиочастотная термодеструкция, абляция

1. Lahat E., Eshkenazy R., Zendel A., Zakai B.B., Maor M., Dreznik Y., Ariche A. Complications after percutaneous ablation of liver tumors: asystematic review. Hepatobiliary Surg. Nutr. 2014; 3 (5): 317–323. DOI: 10.3978/j.issn.2304-3881.2014.09.07.

2. Hinshaw J.L., Lubner M.G., Ziemlewicz T.J., Lee F.T. Jr., Brace C.L. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation – what should you use and why? Radiographics. 2014; 34 (5): 1344–1362. DOI: 10.1016/j.rcl.2015.05.012.

3. Ryan M.J., Willatt J., Majdalany B.S. Ablation techniques for primary and metastatic liver tumors. World J. Hepatol. 2016; 8 (3): 191–199. DOI: 10.4254/wjh.v8.i3.191.

4. Salati U., Barry A., Chou F.Y., Ma R., Liu D.M. State of the ablation nation: a review of ablative therapies for cure in the treatment of hepatocellular carcinoma. Future Oncol. 2017; 13 (16): 1437–1448. DOI: 10.2217/fon-2017-0061.

5. Van der Sluis F.J-F., Bosch J.L., Terkivatan T., de Man R.A., Ijzermans J.N., Hunink M.G. Hepatocellular adenoma: Cost effectiveness of different treatment strategies. Radiology. 2009; 252 (3): 737–746. DOI: 10.1148/radiol.2523082219.

6. Beer E., Kelly H.A., Ward G.E. Discussion of advances in surgery. Arch. Phys. Ther. X-Ray. Radium. 1931; 12: 471–472.

7. Beer E. Removal of neoplasms of the urinary bladder: a new method employing high frequency (Oudin) currents through a cauterizing cystoscope. JAMA. 1910; 54: 1768–1769.

8. Косырев В.Ю. Радиочастотная термоаблация в комбинированном лечении злокачественных опухолей печени (показания, методология, результаты лечения): дисс. ... д-ра мед. наук. М., 2011. 184 с.

9. Poon R.T., Ng K.K., Lam C.M., Ai V., Yuen J., Fan S.T. Radiofrequency ablation for subcapsular hepatocellularcarcinoma. Ann. Surg. Oncol. 2004; 11 (3): 281–289.

10. Wissniowski T.T., Hänsler J., Neureiter D., Frieser M., Schaber S., Esslinger B., Voll R., Strobel D., Hahn E.G., Schuppan D. Activation of tumor-specific T-lymphocytes by radiofrequency ablation of the VX2 hepatoma in rabbits. Cancer Res. 2003; 63 (19): 6496–6500.

11. Zerbini A., Pilli M., Penna A., Pelosi G., Schianchi C., Molinari A., Schivazappa S., Zibera C., Fagnoni F.F., Ferrari C., Missale G. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006; 66 (2): 1139–1146.

12. Shi L., Chen L., Wu C., Zhu Y., Xu B., Zheng X., Sun M., Wen W., Dai X., Yang M., Lv Q., Lu B., Jiang J. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin. Cancer Res. 2016; 22 (5): 1173–1184. DOI: 10.1158/1078-0432.CCR-15-1352.

13. Gish R.G., Lencioni R., Di Bisceglie A.M., Raoul J.L., Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Gastroenterol. Hepatol. 2012; 6 (2): 173–185. DOI: 10.1586/egh.11.105.

14. Jia-Yan Ni. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepato cellular carcinoma. World J. Gastroenterol. 2013; 19 (24): 3872–3882. DOI: 10.3748/wjg.v19.i24.3872.

15. Peng Z.W., Zhang Y.J., Chen M.S., Xu L., Liang H.H., Lin X.J., Guo R.P., Zhang Y.Q., Lau W.Y. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J. Clin. Oncol. 2013; 31 (4): 426–432. DOI: 10.1200/JCO.2012.42.9936.

16. Ding H., Su M., Zhu C., Wang L., Zheng Q., Wan Y. CT-guided versus laparoscopic radiofrequency ablation in recurrent small hepatocellular carcinoma against the diaphragmatic dome. Sci. Rep. 2017; 7: 44583. DOI: 10.1038/srep44583.

17. Eisele R.M., Neumann U., Neuhaus P., Schumacher G. Open surgical is superior to percutaneous access for radiofrequency ablation of hepatic metastases. World J. Surg. 2009; 33 (4): 804–811. DOI: 10.1007/s00268-008-9905-1.

18. Duhwan Yun D., Kim S., Son I., Chun K. Comparative analysis of laparoscopic versus open surgical radiofrequency ablation for malignant liver tumors. Korean J. Hepatobiliary Pancreat. Surg. 2014; 18 (4): 122–128. DOI: 10.14701/kjhbps.2014.18.4.122.

19. Rossi P., Manzelli A., Petrou A., Bramis K., Anselmo A., Iaria G., Toti L., Tommaso T.M., Berlanda M., Tisone G. RFA assisted liver resection combined with hanging manoeuvre: The alternative option for safe and bloodless major hepatectomy. Hellenic J. Surg. 2011; 83 (6): 347–351. DOI: 10.1007/s13126-011-0061-y.

20. Reccia I., Sodergren M.H., Jayant K., Kurz E., Carneiro A., Spalding D., Pai M., Jiao L., Habib N. The journey of radiofrequency-assisted liver resection. Surg. Oncol. 2018; pii: S0960-7404(17)30391-2. DOI: 10.1016/j.suronc.2018.01.004.

21. Fioole B., Jansen M.C., van Duijnhoven F.H., van Hillegersberg R., van Gulik T.M., Borel Rinkes I.H. Combining partial liver resection and local ablation of liver tumours: a preliminary Dutch experience. World J. Surg. Oncol. 2006; 4: 46.

22. Xu L.L., Zhang M., Yi P.S., Zheng X.B., Feng L., Lan C., Tang J.W., Ren S.S., Xu M.Q. Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2017; 37 (6): 974–980. DOI: 10.1007/s11596-017-1836-3.

23. Hatanaka T., Kakizaki S., Yuhei S., Takeuchi S., Shimada Y., Takizawa D., Katakai K., Sato K., Yamada M. Percutaneous radiofrequency ablation for hepatocellular carcinoma located in the caudate lobe of the liver. Acta Gastroenterol. Belg. 2015; 78 (3): 267–273.

24. Косырев В.Ю., Долгушин Б.И., Мартынков Д.В., Шолохов В.Н. Сравнение эффективности чрескожной радиочастотной аблации опухолей печени в зависимости от метода навигации. Пленум правления Ассоциации хирургов-гапатологов стран СНГ: материалы. М., 2013. C. 26–27.

25. Bale R., Schullian P., Schmuth M., Widmann G., Jaschke W., Weinlich G. Stereotactic radiofrequency ablation for metastatic melanoma to the liver. Cardiovasc. Intervent. Radiol. 2016; 39 (8): 1128–1135. DOI: 10.1007/s00270-016-1336-z.

26. Bale R., Schullian P., Haidu M., Widmann G. Stereotactic Radiofrequency Ablation (SRFA) of intrahepatic cholangiocellular carcinomas: a minimal invasive alternative to liver resection. Wien Med. Wochenschr. 2013; 163 (5–6): 128–131. DOI: 10.1007/s10354-013-0182-8.

27. Bale R., Widmann G., Schullian P., Haidu M., Pall G., Klaus A., Weiss H., Biebl M., Margreiter R. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur. Radiol. 2012; 22 (4): 930–937. DOI: 10.1007/s00330-011-2314-0.

28. Cazzato R.L., Garnon J., Ramamurthy N., Tsoumakidou G., Imperiale A., Namer I.J., Bachellier P., Caudrelier J., Rao P., Koch G., Gangi A. 18F-FDOPAPET/CT-Guided radiofrequency ablation of liver metastases from neuroendocrine tumours: Technical noteona preliminary experience. Cardiovasc. Intervent. Radiol. 2016; 39 (9): 1315–1321. DOI: 10.1007/s00270-016-1334-1.

29. Zhao Z., Wu J., Liu X., Liang M., Zhou X., Ouyang S., Yao J., Wang J., Luo B. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett. 2018; 421: 73–81. DOI: 10.1016/j.canlet.2018.02.024.

30. Vincenzi B., Di Maio M., Silletta M., D’Onofrio L., Spoto C., Piccirillo M.C., Daniele G., Comito F., Maci E., Bronte G., Russo A., Santini D., Perrone F., Tonini G. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with locoregional therapies: a literature-based meta-analysis. PLoS One. 2015; 10 (7): e0133488. DOI: 10.1371/journal.pone.

31. Samim M., Molenaar I.Q., Seesing M.F., van Rossum P.S., van den Bosch M.A., Ruers T.J., Borel Rinkes I.H., van Hillegersberg R., Lam M.G., Verkooijen H.M. The diagnostic performance of 18F-FDG PET/CT, CT and MRI in the treatment evaluation of ablation therapy for colorectal liver metastases: A systematic review and meta-analysis. Surg. Oncol. 2017; 26 (1): 37–45. DOI: 10.1016/j.suronc.2016.12.006.

32. Huang Y.Z., Zhou S.C., Zhou H., Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013; 60 (125): 1131–1135. DOI: 10.5754/hge121142.

33. Yi P.S., Huang M., Zhang M., Xu L., Xu M.Q. Comparison of transarterial chemoembolization combined with radiofrequency ablation therapy versus surgical resection for early hepatocellular carcinoma. Am. Surg. 2018; 84 (2): 282–288.

34. Guo W., He X., Li Z., Li Y. Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on survival outcome of early hepatocellular carcinoma: A meta-analysis. Hepatogastroenterology. 2015; 62 (139): 710–714.

35. Yang W., Yan K., Goldberg S.N., Ahmed M., Lee J.C., Wu W., Zhang Z.Y., Wang S., Chen M.H. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J. Gastroenterol. 2016; 22 (10): 2993–3005. DOI: 10.3748/wjg.v22.i10.2993.

36. Zhou Y., Zhao Y., Li B., Xu D., Yin Z., Xie F., Yang J. Metaanalysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterology. 2010; 10: 78. DOI: 10.1186/1471-230X-10-78.

37. Feng Q., Chi Y., Liu Y., Zhang L., Liu Q. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies. J. Cancer Res. Clin. Oncol. 2015; 141 (1): 1–9. DOI: 10.1007/s00432-014-1708-1.

38. Wang Y., Luo Q., Li Y., Deng S., Wei S., Li X. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One. 2014; 9 (1): e84484. DOI: 10.1371/journal.pone.0084484.

39. Qi X., Tang Y., An D., Bai M., Shi X., Wang J., Han G., Fan D. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J. Clin. Gastroenterol. 2014; 48 (5): 450–457. DOI: 10.1097/MCG.0000000000000008.

40. Lan T., Chang L., Rahmathullah M.N., Wu L., Yuan Y.F. Comparative efficacy of interventional therapies for early-stage hepatocellular carcinoma: A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2016; 95 (15): e3185. DOI: 10.1097/MD.0000000000003185.

41. Yang B., Zan R.Y., Wang S.Y., Li X.L., Wei M.L., Guo W.H., You X., Li J., Liao Z.Y. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J. Surg. Oncol. 2015; 13: 96. DOI: 10.1186/s12957-015-0516-7.

42. Chen S., Peng Z., Xiao H., Lin M., Chen Z., Jiang C., Hu W., Xie X., Liu L., Peng B., Kuang M. Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery. Int. J. Hyperthermia. 2017: 1–9. DOI: 10.1080/02656736.2017.1387941.

43. Porrett P.M., Peterman H., Rosen M., Sonnad S., Soulen M., Markmann J.F., Shaked A., Furth E., Reddy K.R., Olthoff K. Lack of benefit of pretransplant locoregional hepatic therapy for hepatocellular cancer in the current MELD Era. Liver Transplantation. 2006; 12 (4): 66